Survey of current retinopathy of prematurity practices in China
Author:
Corresponding Author:

Michelle T Cabrera. OA.9.220, 4800 Sand Point Way NE, Seattle, WA 98105, USA. cabreram@uw.edu

Fund Project:

Supported by Research to Prevent Blindness and the NIH CORE Grant (No.EY001730).

  • Article
  • | |
  • Metrics
  • |
  • Reference [20]
  • |
  • Related [20]
  • | | |
  • Comments
    Abstract:

    AIM: To understand retinopathy of prematurity (ROP) screening and treatment preferences among Chinese ophthalmologists. METHODS: A Chinese language survey was administered anonymously using WebQ (Catalyst, Seattle, WA, USA) among Chinese ROP screeners from December 2016 to January 2017. RESULTS: Among 70 ophthalmologists contacted, 65 responded (93%; 78% female, mean age 40y, 57% pediatric ophthalmologists and 25% retina specialists). Most used screening criteria of birth weight ≤2 kg (62%) with variation in cut-off gestational age (≤37wk, 34%; ≤34wk, 22%; ≤32wk, 31%). RetCam (Natus Medical Incorporated, Pleasanton, CA, USA) wide-field fundus photography assisted most screeners (72%) and was exclusively used by many (29%). Among 55 ophthalmologists treating ROP, anti-vascular endothelial growth factor (VEGF) was preferred over laser for both zone I (76% vs 24%) and zone II ROP (58% vs 42%). Retina specialists (P=0.004) and ophthalmologists with >3mo of training (P=0.03) were more likely to use anti-VEGF over laser for zone I ROP. Lack of laser training (8/20, 40%), access (6/20, 30%) and anesthesia (4/20, 20%) were common barriers to laser treatment. CONCLUSION: Chinese ROP screeners favor anti-VEGF injection and RetCam imaging for ROP management. A better understanding of ROP screening and treatment informs future research and education efforts in China.

    Reference
    1 Good WV, Hardy RJ, ETROP Multicenter Study Group. The multicenter study of early treatment for retinopathy of prematurity (ETROP). Ophthalmology 2001;108(6):1013-1014.
    2 Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364(7):603-615.
    3 Zin A, Gole GA. Retinopathy of prematurity-incidence today. Clin Perinatol 2013;40(2):185-200.
    4 Chen Y, Feng J, Li FT, Yin H, Liang JH, Li XX. Analysis of changes in characteristics of severe retinopathy of prematurity patients after screening guidelines were issued in China. Retina 2015;35(8): 1674-1679.
    5 Mora JS, Waite C, Gilbert CE, Breidenstein B, Sloper JJ. A worldwide survey of retinopathy of prematurity screening. Br J Ophthalmol 2018;102(1):9-13.
    6 Asano MK, Dray PB. Retinopathy of prematurity. Disease-a-Month 2014;60(6):282-291.
    7 Huang QJ, Zhang Q, Fei P, Xu Y, Lyu J, Ji XD, Peng J, Li YA, Zhao PQ. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors. Ophthalmology 2017;124(8):1156-1164.
    8 Gunay M, Sukgen EA, Celik G, Kocluk Y. Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Curr Eye Res 2017;42(3):462-469.
    9 Lyu J, Zhang Q, Chen CL, Xu Y, Ji XD, Li JK, Huang QJ, Zhao PQ. Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors. Invest Ophthalmol Vis Sci 2017;58(3):1719.
    10 Tawse KL, Jeng-Miller KW, Baumal CR. Current practice patterns for treatment of retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina 2016;47(5):491-495.
    11 Multicenter trial of cryotherapy for retinopathy of prematurity. Three-month outcome. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1990;108(2):195-204.
    12 Sekeroglu MA, Hekimoglu E, Sekeroglu HT, Arslan U. Retinopathy of prematurity: a nationwide survey to evaluate current practices and preferences of ophthalmologists. Eur J Ophthalmol 2013;23(4):546-552.
    13 Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, Tawansy KA, Mintz-Hittner HA. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment. JAMA Ophthalmol 2014;132(11):1327.
    14 Lepore D, Quinn GE, Molle F, Orazi L, Baldascino A, Ji MH, Sammartino M, Sbaraglia F, Ricci D, Mercuri E. Follow-up to age 4y of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology 2018;125(2):218-226.
    15 Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ, Smith OE, Steinkuller PG. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Investig Ophthalmol Vis Sci 2015;56(2):956-961.
    16 Chinese Ophthalmological Society CMA. Guidelines for retinopathy of prematurity screening in China. Zhonghua Yan Ke Za Zhi 2014;50(12): 933-935.
    17 Zhang XX, Wang YP, Ulrich JN, Yang Y, Ding L, Yang Y, Xu D, Tarczy-Hornoch K, Cabrera MT. Evaluation of retinopathy of prematurity incidence with telemedicine confirmation in Gansu, China: a pilot study. Ophthalmic Epidemiol 2018; 25(2):120-125.
    18 Quinn GE, Ying GS, Daniel E, Hildebrand PL, Ells A, Baumritter A, Kemper AR, Schron EB, Wade K. Validity of a telemedicine system for the evaluation of acute-phase retinopathy of prematurity. JAMA Ophthalmol 2014;132(10):1178.
    19 Vartanian RJ, Besirli CG, Barks JD, Andrews CA, Musch DC. Trends in the screening and treatment of retinopathy of prematurity. Pediatrics 2017;139(1):e20161978.
    20 Sun YL, Gregersen H, Yuan W. Chinese health care system and clinical epidemiology. Clin Epidemiol 2017;9:167-178.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Thao Phuong Le, Jing Feng, Leona Ding,/et al.Survey of current retinopathy of prematurity practices in China. Int J Ophthalmol, 2021,14(8):1241-1247

Copy
Share
Article Metrics
  • Abstract:1251
  • PDF: 638
  • HTML: 0
  • Cited by: 0
Publication History
  • Received:January 18,2020
  • Revised:September 01,2020
  • Online: June 28,2021